Statistically significant differences compared with Placebo MDI were noted at almost all doses for the secondary FEV@ parameters ( P @ ) except @-hour trough FEV@ at @ g. All doses were safe and well tolerated in this study ; the most frequently reported adverse event was dry mouth ( @-@ @ % across doses ; @ % for Placebo MDI , and @ % for TIO ) .